Market revenue in 2023 | USD 288.6 million |
Market revenue in 2030 | USD 534.8 million |
Growth rate | 9.2% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 55.86% in 2023. Horizon Databook has segmented the France biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
The country has 4,233 researchers per million inhabitants, and the large pool of skilled professionals as well as the high R&D spending to boost advancements are likely to drive the CRO market. France is the third-largest trials market in Europe (just after the UK and Germany).
Approximately, 16,800 commercial clinical trial sites are currently active in France, which has increased by 20% between June 2016 and May 2017. Since 2002, the French Association of Pharmaceutical Companies (LEEM) have surveyed key players in the market every alternate year to explore their research.
The 2012 survey included 30 companies representing 68% of the French market. The research involved 79 countries, 420 phases I/II, II, and III studies. The patient recruitment rates are also high in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the France biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into France biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account